BioCryst (Nasdaq:BCRX) granted equity awards to nine new employees under Nasdaq Listing Rule 5635(c)(4). Grants include stock options for an aggregate 33,950 shares at a $8.57 exercise price and RSUs covering 80,650 shares. Awards vest in four annual installments and options have 10-year terms.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – BCRX
-1.68%
-1.68%Session close to close
In the Jun 10 session, BCRX declined 1.68%, reflecting a mild negative market reaction.
This announcement details routine inducement equity grants to nine new employees, totaling 33,950 st...
Analysis
This announcement details routine inducement equity grants to nine new employees, totaling 33,950 stock options and 80,650 RSUs at an exercise price of $8.57, vesting over four years. It follows a series of more material updates, including recent HAE data presentations and a European licensing deal for navenibart. Investors monitoring BioCryst may focus more on upcoming clinical milestones, revenue trends, and additional partnership activity than on this administrative equity action.
Key Figures
Inducement stock options:33,950 sharesInducement RSUs:80,650 sharesExercise price:$8.57 per share+5 more
8 metrics
Inducement stock options33,950 sharesAggregate options granted to nine new employees as of June 1, 2026
Inducement RSUs80,650 sharesAggregate RSUs granted to nine new employees as of June 1, 2026
Exercise price$8.57 per shareStock option exercise price equal to June 1, 2026 close
Vesting schedule4 equal annual installmentsOptions and RSUs vest over four years starting one year after grant
Option term10 yearsEach inducement stock option’s contractual term
New hires9 employeesNumber of newly hired employees receiving inducement grants
Current share price$8.43Price prior to publication on June 9, 2026
Market capitalization$2,142,591,224Market cap prior to the news
European license for navenibart with $70M upfront and milestone/royalty terms.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent positive R&D and partnership news generally aligned with upward price moves, while administrative or mixed financial updates saw modest reactions.
Recent Company History
Over the last several weeks, BioCryst reported multiple updates, including new HAE data presentations at EAACI and ISPOR in May 2026, both followed by gains of 7.67% and 9.09%. An earnings update on May 6 with strong ORLADEYO revenue but a large GAAP loss led to a modest -2.21% move. A European licensing deal for navenibart on May 4 produced a small 0.11% uptick. A prior inducement RSU grant on May 5 coincided with a mild -1.85% reaction.
Key Terms
nasdaq listing rule 5635(c)(4), stock options, restricted stock units (rsus), exercise price, +2 more
6 terms
nasdaq listing rule 5635(c)(4)regulatory
"granted in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
stock optionsfinancial
"granted nine newly-hired employees stock options to purchase an aggregate"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
restricted stock units (rsus)financial
"and restricted stock units (RSUs) covering an aggregate of 80,650 shares"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
exercise pricefinancial
"The options have an exercise price of $8.57 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"The options and RSUs vest in four equal annual installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
inducement equity incentive planfinancial
"subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan"
An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.
RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 80,650 shares, of BioCryst common stock. The options and RSUs were granted as of June 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $8.57 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors: investorrelations@biocryst.com
Media: media@biocryst.com
FAQ
What inducement equity awards did BioCryst (BCRX) grant on June 1, 2026?
BioCryst granted stock options for 33,950 shares and RSUs for 80,650 shares to nine new employees. According to BioCryst, these awards are inducement grants made under its Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
What is the exercise price of the new BioCryst (BCRX) stock options granted in June 2026?
The new BioCryst stock options have an exercise price of $8.57 per share. According to BioCryst, this price equals the closing price of its common stock on the June 1, 2026 grant date, aligning the awards with then-current market value.
How do the June 2026 BioCryst (BCRX) inducement options and RSUs vest?
The BioCryst inducement options and RSUs vest in four equal annual installments. According to BioCryst, vesting begins on the one-year anniversary of the June 1, 2026 grant date and is conditioned on each new employee’s continued service with the company.
What is the term of the BioCryst (BCRX) inducement stock options granted in 2026?
Each BioCryst inducement stock option granted on June 1, 2026 has a 10-year term. According to BioCryst, these options are governed by the company’s Inducement Equity Incentive Plan and individual stock option agreements detailing applicable terms and conditions.
Why did BioCryst (BCRX) use Nasdaq Listing Rule 5635(c)(4) for these June 2026 grants?
BioCryst used Nasdaq Listing Rule 5635(c)(4) to issue inducement equity awards to new hires. According to BioCryst, the options and RSUs were material inducements for nine employees to join the company and were granted outside shareholder-approved plans under this rule.
